Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1305 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

McKesson Q3 revenues marginally fall

For the third quarter of 2010, the company posted a net income of $155m, compared to $326m for the same period in 2009. McKesson’s operating income for the

FDA launches early probes on Sanofi, Takeda drugs

The agency is reviewing a possible interaction between Sanofi’s heart drug Multaq and the blood thinner Warfarin that could lead to an ‘increased anticoagulant effect’. Takeda’s diabetes drug

ALK, Torii Pharma sign licensing pact

The tie up licenses Torlii Pharma for the development, marketing and distribution of Mitizax, ALK’s tablet which is indicated for the treatment of house dust allergy. As per

Caraco Pharma Q3 net sales down

For the third quarter of 2010, the company’s operating loss was $4.99m, compared to $5.07m for the same period in 2009. Net loss was $3.04m, compared to $3.03m